Agree. A person selling is just a small cog in the massive

New Post Public Reply Private Reply Replies (0) Message Board
PatientLong bigO #73451
495
Agree. A person selling is just a small cog in the massive thing we call the market. The market has no personality, and it is useless to get "mad" at it. Be smarter than the market.

I have made the calculated determination in keeping with my risk tolerance to invest in CYDY for its long-term, amazing prospects in several indications. Energy spent worrying daily about who is selling, market makers playing games, etc., is wasted energy.

I can hardly fathom getting bad data from CD12. I find that a highly unlikely prospect in light of all the evidence to-date. However, if we do, it will be another great buying opportunity. Remember, this was never a COVID drug until 9 months ago.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring the $2.7 Billion Bid for Papa John’s: An Investment Insight

Updated Category News Views 229

Papa John’s $2.7 Billion Takeover Bid: Insights into Potential Value Recently, shares of Papa John’s International Inc (NASDAQ:PZZA) experienced a notable surge, leading to a halt in trading due to high volatility. This surprising movement came in light of credible reports suggesting a take-private cash offer of $65 per share from TriArtisan Capital Advisors, totaling...

Continue Reading
Key Highlights from Octopus Apollo VCT plc AGM Results

Updated Category News Views 105

Octopus Apollo VCT plc AGM Results Overview Octopus Apollo VCT plc recently conducted its Annual General Meeting (AGM), showcasing significant engagement from shareholders. The meeting aimed to discuss key resolutions impacting the future direction of the company. Voting Outcomes of the AGM The company disclosed that all resolutions were successfully passed during the...

Continue Reading
Carisma Therapeutics Showcases Strong Financial Performance

Updated Category News Views 104

Carisma Therapeutics Showcases Strong Financial Performance Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, recently released its financial performance for the third quarter of 2024. With a focus on developing innovative immunotherapies, Carisma provided insight into its ongoing projects. Key Developments and Milestones Carisma's...

Continue Reading
Epinephrine Market Growth Insights and Future Potential

Updated Category News Views 112

Overview of the Epinephrine Market The global epinephrine market is on a significant upswing, with recent evaluations estimating its value at USD 3.11 billion and a projected growth to approximately USD 6.39 billion within the next decade. As a critical hormone and neurotransmitter produced by the adrenal glands, epinephrine is essential in treating severe allergic...

Continue Reading
Canadian North Resources Achieves Major Milestones in Q2 2025

Updated Category News Views 183

Canadian North Resources Makes Significant Progress in Operational Strategy Highlights: Canadian North has expanded its bio-metallurgical programs significantly, achieving impressive nickel and cobalt extraction rates through innovative bio-leaching tests. The focus remains on extracting copper and other precious group elements (PGE) metals from the Ferguson Lake Project....

Continue Reading